Only one FDA-approved β-lactamase inhibitor has ever been orally available: clavulanic acid, approved in 1984. Avibactam, approved by FDA in 2015, is the first of a new class of BLIs called diazabicyclooctanes, or "DBOs". This class has much broader coverage than clavulanic acid but can only be administered by intravenous injection. Herein, we describe the synthesis and testing of the first approved BLI to be rendered orally bioavailable since clavulanic acid (1984).
■ INTRODUCTION
The present and growing threat of microorganisms resistant to current antibiotics is an issue that commands worldwide attention. 1, 2 In 1976, the first β-lactamase inhibitor (clavulanic acid) was discovered 3, 4 and later commercialized in combination with a β-lactam antibiotic (amoxicillin) as an oral/ intravenous drug (Augmentin). β-Lactamase inhibitors (BLIs), while lacking significant antibiotic activity themselves, protect β-lactam antibiotics from destructive deactivating enzymes produced by microorganisms (β-lactamases). 5, 6 Since the 1980s, BLI/antibiotic combinations have become a standard part of therapy. 7−10 In the over 40 years since the discovery of clavulanic acid, several other β-lactam derived BLIs have been discovered and approved by FDA, 11 but none are orally available. A significant consequence of these BLIs being intravenous only is that they may not be given outside the hospital, greatly increasing treatment costs.
In the mid-1990s an important new class of non-β-lactam containing BLIs was discovered. 12−15 These interesting compounds, diazabicyclooctanones (DBOs), proved to be potent inhibitors of several classes of therapeutically important β-lactamases, and one has been FDA approved (avibactam 1, Figure 1 ). 15 Several other DBOs are being progressed clinically (2, 3, 4), 11, 16 but they also are intravenous only. 17 Because of the continuous evolution or change in the prevalence of lactamases, most oral β-lactam antibiotics have lost potency since they were first commercialized (∼1990s). If an oral BLI with much better coverage of β-lactamases than clavulanic acid could be discovered and combined with an oral β-lactam antibiotic, the combination could restore the antibiotic to its original potency levels.
■ RESULTS
Considering the avibactam structure as it relates to oral absorption, attention is drawn to the unusual O-sulfated hydroxamic acid functionality as originally described in 1982 by Gordon. 18 Historical medicinal chemistry suggests a charged sulfate moiety should be viewed as a primary obstacle to good oral bioavailability. 19 The other DBOs in development also contain similar sulfate groups.
No strategies or methods to prepare prodrugs of sulfate containing drugs have been described in the chemical literature. Esters of sulfates are generally considered to be alkylating agents. However, an important observation was described in 2006 by Widlanski 20 who showed that neopentyl groups and to a lesser extent isobutyl groups could be used as protecting groups on sulfates. In particular, the neopentyl groups were shown to be extremely stable, requiring high temperatures and aggressive nucleophiles for removal. This represents a pathway by which a sulfate ester could be modified as a stable, unreactive entity and might be the first step in sulfate prodrug design; 21 vide infra.
In order to synthesize avibactam O-neopentyl esters, a variety of approaches were undertaken. The most effective of these is described in Figure 2 .
Hydrogenolysis of O-benzyl intermediate 5 provided Nhydroxy 6 in quantitative yield. 21 Compound 6 had been reported to be unstable and was used immediately. Sulfuryl chloride was reacted with 2,2,dimethylpropanol to give the chlorosulfonate 7, which was then reacted with 6 affording sulfate ester 9 as an isolable, stable compound.
To use this methodology in prodrug design, we needed to overcome the reported difficult removal of the neopentyl group and to perform this under conditions amenable to removal in vivo. This was achieved by employing an intramolecular displacement of sulfate 1 (avibactam). Hydroxypivalic acid was esterified as the benzyl ester and allowed to react with sulfuryl chloride (8) and combined with 6 to yield stable 10. To test whether the free acid would perform the intramolecular displacement of avibactam under mild conditions, the benzyl ester was hydrogenated under neutral conditions.
To mimic what might occur in vivo, hydrogenolysis of 10 afforded the intermediate carboxylic acid 11 which rapidly expelled avibactam. These mild conditions suggested that esterase cleavage in vivo could trigger the expulsion of avibactam systemically. In addition to expulsion of avibactam, fragmentation of the promoiety was shown by 1 H and 13 C NMR to produce pivalolactone by comparison with an authentic sample (Supporting Information). The rate of the intermediate acid expulsion of avibactam and production of pivalolactone was shown to be greatly accelerated when slightly less than 1 equiv of NaHCO 3 was used.
The presence of the essential gem-dimethyl group in the promoiety, besides providing steric hindrance to prevent nucleophilic attack at the methylene adjacent to sulfate oxygen, also importantly exerts a gem-substituent/trimethyl lock effect 22, 23 which brings the carboxylate nucleophile closer to the displacement site. When tested in vivo, the immediate products of ester/esterase cleavage are avibactam 1 and pivalolactone 12, which is quickly hydrolyzed by water and esterases to hydroxypivalic acid 13. The breakdown of 10 triggered by ester cleavage is illustrated in Figure 3 . Intramolecular formation of the strained β-lactone (4-exotet) 24 ,25 during displacement is driven by the O-sulfated hydroxamic acid (avibactam) being an excellent leaving group. 26 The conclusions of Widlanski which stated that neopentyl sulfates were stable except to severe conditions were further confirmed by showing that 8 did not react with cysteinyl or glutathionyl organic soluble derivatives (as 10 is not soluble in water). The individual potential alkylation products were synthesized but were not observed when the nucleophiles were incubated with 10 for 24 h at both ambient temperature and 37°C (see Supporting Information).
Compound 10 and several related ester analogs (14−20) were prepared by the above route and were tested for their oral bioavailability of avibactam in rat, monkey, and dog PK assays (details in Supporting Information). To be considered useful as a drug, compounds generally need to achieve F = 30% or better. The compounds listed in Table 1 meet this criterion. For comparison, the oral bioavailability of avibactam was ∼1% rat, 15% dog, 3% monkey.
The general concept of displacing avibactam, by revealing through esterase cleavage an appropriately placed nucleophile as shown in 11, was extended to several other prodrug chemotypes in which the nucleophile and chain length of the promoiety were varied. Chemotypes 18, 19, 20 were also shown to be bioavailable in rat, monkey, dog (Table 1) . Their expected cleavage products are shown in Figure 4 .
■ DISCUSSION AND CONCLUSIONS
Approximately 65% of all prescriptions for antibiotics are βlactams−penicillins, cephalosporins, carbapenams, and monobactams. 5 The most prevalent resistance mechanism to these drugs is a family of 2700+ β-lactamase enzymes produced by bacteria that destroy β-lactam antibiotics. For many years now there have been no new safe and effective FDA-approved oral antibiotics with broad coverage for serious Gram-negative infections. Patients who in past years could have been treated 
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To this end, a novel method of preparing prodrugs (and potentially protecting sulfates) 27 of sulfate containing drugs was developed and applied to avibactam. The novel entities produced were shown to have significant bioavailability in rat, monkey, and dog. Variations of the overall strategy employing a neopentyl center proximate to sulfate, and an endogenous enzyme triggered nucleophile (nucleophile can be varied, as can chain length) to perform the intramolecular displacement have been applied to design other promoieties. We also applied this prodrug methodology to other DBOs. These results will be reported in due course.
■ EXPERIMENTAL SECTION
General. All reagents were purchased from commercial suppliers and used without further purification. All solvents were reagent or HPLC grade. Analytical TLC was performed on silica gel 60 F254 plates and visualized by UV if possible or by staining with KMnO 4 dip or phosphomolybdic acid in EtOH dip. Flash chromatography was carried out using an automated system with prepacked silica columns. Yields refer to isolated yields of pure compounds (>95% purity characterized by 1 H, 13 C NMR, HPLC, MS, and for key compounds HRMS (Supporting Information). 1 H NMR and 13 C NMR spectra were recorded on a 300 MHz spectrometer at ambient temperature. Chemical shifts are reported in parts per million (ppm) relative to deuterated solvent or a TMS internal standard. Multiplicities are reported as follows: s = singlet; d = doublet, t = triplet; m = multiplet; br = broad.
Preparation of (2S,5R)-6-Hydroxy-7-oxo-1,6-diazabicyclo- General Method for Related Chlorosulfonyloxy Intermediates. Preparation of Neopentyl Sulfurochloridate (7) . 20 Sulfuryl chloride (0.11 mL, 1.4 mmol) in Et 2 O (20 mL) was added dropwise to a stirred solution of 2,2-dimethylpropan-1-ol (0.21 g, 2.3 mmol) and pyridine (0.11 mL, 1.4 mmol) in Et 2 O (5 mL) at −78°C under an atmosphere of nitrogen. The mixture was stirred at −78°C for 30 min, then filtered through a pad of Celite. The filtrate containing a solution of the desired product in Et 2 O was used directly in the next step without further purification or concentration.
Preparation of (2S ,5R )-2-Carbamoyl-7-oxo-1,6diazabicyclo[3.2.1]octan-6-ylneopentyl Sulfate (9) . (2S,5R)-6-Hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (0.20 g, 1.1 mmol) was suspended in THF (50 mL), and the resulting suspension was cooled to 0°C under an atmosphere of nitrogen. 1,8-Diazabicyclo[5.4.0]undec-7-ene (177 μL, 1.2 mmol) was added slowly to the cooled solution, and the mixture was stirred for 10 min. A solution of neopentyl sulfurochloridate (0.25 g, 1.3 mmol) in Et 2 O was added to the reaction mixture in one portion. The mixture was stirred at 0°C and then allowed to warm slowly to ambient temp and stirred overnight. The solution was decanted from the solid which had precipitated from the reaction mixture, and the solid was rinsed with EtOAc (×2). The combined organic layers were concentrated under vacuum, and the resulting solid was dissolved in DCM and purified by column chromatography on silica gel (12 g column) using EtOAc/ hexanes (1:9 to 7:3) as eluent to give a solid product. The solid was triturated with MTBE to give the product (142 mg). The filtrate was concentrated to give another aliquot of product (50 mg). The total yield = 53%. LCMS: m/z = 335.95 [M + H] + . 1 was added dropwise, and the mixture was stirred at −78°C for 10 min. A solution of ethyl 3-((chlorosulfonyl)oxy)-2,2-dimethylpropanoate 8 (538 mg, 2.2 mmol) in THF (1 mL) was then added quickly to the reaction mixture via syringe. The syringe was rinsed with THF (3 × 0.5 mL), each rinse being added to the reaction mixture. After 10 min at −78°C, the reaction mixture was allowed to warm to room temperature and stirred at room temperature until judged complete by LCMS and TLC analysis (∼2 h). EtOAc (20 mL) and saturated aqueous NaHCO 3 (20 mL) were added, and the organic and aqueous layers were partitioned. The organic layer was washed with saturated NaHCO 3 (20 mL), H 2 O (3 × 20 mL), brine (20 mL), dried (Na 2 SO 4 ), and concentrated under vacuum to leave a crude residue. The residue was purified by column chromatography on silica gel using EtOAc/hexanes (1:9 to 1:0) as eluent to give the product (318 mg, 39%) as a solid. LCMS: m/z = 394. 
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